Reuters logo
BRIEF-Ultragenyx and Kyowa Hakko Kirin announce FDA not currently planning to hold advisory committee meeting for Burosumab biologics license application
November 1, 2017 / 12:41 PM / 21 days ago

BRIEF-Ultragenyx and Kyowa Hakko Kirin announce FDA not currently planning to hold advisory committee meeting for Burosumab biologics license application

Nov 1 (Reuters) - Ultragenyx Pharmaceutical Inc

* Ultragenyx and Kyowa Hakko Kirin announce FDA not currently planning to hold advisory committee meeting for Burosumab biologics license application

* Ultragenyx Pharmaceutical Inc - ‍Additionally, FDA indicated that review is proceeding according to its internal review timelines​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below